期刊
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 23, 2021
卷 23, 期 -, 页码 385-405出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-bioeng-070620-033348
关键词
CAR T cell therapy; nanoparticle; gene therapy; off-the-shelf T cell therapy
资金
- National Cancer Institute [CA207407]
- Mark Foundation for Cancer Research
- Alliance for Cancer Gene Therapy
- Allen Distinguished Investigator Award
- Paul G. Allen Frontiers Group advised grant of the Paul G. Allen Family Foundation
Gene therapy enables the creation of CAR-T cells to target specific diseases, but current manufacturing protocols are costly and complex, limiting access for many patients. In vivo programming of T cells could potentially overcome these challenges and expand the reach of this therapy.
Gene therapy makes it possible to engineer chimeric antigen receptors (CARs) to create T cells that target specific diseases. However, current approaches require elaborate and expensive protocols to manufacture engineered T cells ex vivo, putting this therapy beyond the reach of many patients who might benefit. A solution could be to program T cells in vivo. Here, we evaluate the clinical need for in situ CAR T cell programming, compare competing technologies, review current progress, and provide a perspective on the long-term impact of this emerging and rapidly flourishing biotechnology field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据